NASDAQ:FULC Fulcrum Therapeutics Q3 2026 Earnings Report $3.69 +0.01 (+0.27%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$3.70 +0.00 (+0.14%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Fulcrum Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.07Beat/MissN/AOne Year Ago EPSN/AFulcrum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFulcrum Therapeutics Announcement DetailsQuarterQ3 2026Date10/29/2026TimeBefore Market OpensConference Call DateWednesday, October 28, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Fulcrum Therapeutics Earnings HeadlinesFulcrum Therapeutics consensus price target raised 11.22% to $7.75October 2 at 3:21 PM | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Rated "Reduce" by Sell-Side BrokeragesSeptember 26, 2026 | americanbankingnews.comThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.October 4 at 1:00 AM | Stansberry Research (Ad)BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)September 23, 2026 | globenewswire.comKaplan Fox Reminds Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Ongoing Securities Law InvestigationSeptember 23, 2026 | theglobeandmail.comKaplan Fox Urges Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to Contact the Firm Regarding a Securities InvestigationSeptember 21, 2026 | theglobeandmail.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC) is a clinical-stage biopharmaceutical company focused on developing medicines for genetically defined diseases. The company uses its biology and drug-discovery platform to identify molecular targets that can alter gene expression and address the underlying causes of serious disorders. Fulcrum’s lead investigational program has been losmapimod, a small-molecule p38 alpha and beta mitogen-activated protein kinase inhibitor studied as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive muscle disease. The company has also evaluated other targeted drug candidates for diseases including cancer and hematologic conditions, although programs and development priorities may change as clinical data become available. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum serves patients and healthcare markets through its research and clinical-development activities, primarily in the United States and through global clinical studies. The company is led by Robert J. Gould, Ph.D., who has served as president and chief executive officer and as a member of the board of directors.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the Test Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
